Biotan Laboratories (India) Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 22-12-2024
- Paid Up Capital ₹ 0.50 M
as on 22-12-2024
- Company Age 32 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.00 M
as on 22-12-2024
- Revenue -13.99%
(FY 2023)
- Profit 38.84%
(FY 2023)
- Ebitda 71.76%
(FY 2023)
- Net Worth -12.79%
(FY 2023)
- Total Assets 45.05%
(FY 2023)
About Biotan Laboratories (India)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹1.00 M.
Subramanian Jayapalan, Mohan Sakthivel, Krishnasamy Saranya, and One other member serve as directors at the Company.
- CIN/LLPIN
U24246TN1992PLC023003
- Company No.
023003
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
02 Jul 1992
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Biotan Laboratories (India)?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mohan Sakthivel  | Director | 19-Jan-2004 | Current |
| Subramanian Jayapalan | Director | 10-Dec-2011 | Current |
| Krishnasamy Saranya | Director | 10-Dec-2011 | Current |
| Radhakrishnan Nagarajan | Director | 18-Mar-2021 | Current |
Financial Performance of Biotan Laboratories (India).
Biotan Laboratories (India) Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 13.99% decrease. The company also saw a substantial improvement in profitability, with a 38.84% increase in profit. The company's net worth observed a substantial decline by a decrease of 12.79%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biotan Laboratories (India)?
In 2023, Biotan Laboratories (India) had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Innovative Healthcare (India) Private LimitedActive 24 years 10 monthsMohan Sakthivel is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of Hyderabad Creation Date: 07 Sep 2000 | ₹1.00 M | Open |
How Many Employees Work at Biotan Laboratories (India)?
Unlock and access historical data on people associated with Biotan Laboratories (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biotan Laboratories (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biotan Laboratories (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
